ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
  • Abstract Number: 813
    Citrulline Specific CD4+ T Cells Exhibit a Th1 Memory Phenotype In Rheumatoid Arthritis Subjects and Their Ex Vivo Frequency Is Influenced By Both Disease Duration and Biologic Therapy
  • Abstract Number: 256
    Classification Of Alignment By Self-Report Versus Radiograph Results In Unexpected and Discrepant Pain and Functional Outcomes
  • Abstract Number: 2436
    Classification Of Axspa Based On Positive Imaging (Radiographs and/or MRI of the Sacroiliac Joints) By Local Rheumatologists Or Radiologists Versus Central Trained Readers In The DESIR-Cohort
  • Abstract Number: 1924
    Cleveland Clinic Dual Energy X-Ray Absorptiometry Registry, A Web-Based Tool Designed For Efficient Collection Of Bone Density and Osteoporosis Related Clinical Risk Factor Data
  • Abstract Number: 2190
    Clinical and Immunologic Description Of Pediatric Conditions With Interferon-Regulated Gene Signatures (Chronic Atypical Neutrophilic Dermatosis Lipodystrophy Elevated Tempature, Aicardi Goutieres Syndrome, Juvenile Dermatomyositis, Juvenile Systemic Lupus Erythematosus)
  • Abstract Number: 2073
    Clinical and Prognostic Factors Associated With Survival In Mexican Patients With Idiopathic Inflammatory Myopathies
  • Abstract Number: 1437
    Clinical and Radiographic Outcomes At Two Years and The Effect Of Tocilizumab Discontinuation Following Sustained Remission In The Second Year Of The ACT-RAY Study
  • Abstract Number: 1464
    Clinical and Radiographic Outcomes With Etanercept and Etanercept and Methotrexate In Patients With Rheumatoid Arthritis: Two-Year Results From The Canadian Methotrexate and Etanercept Outcome Study (CAMEO)
  • Abstract Number: 799
    Clinical and Radiological Outcomes Of Two Years Remission Steered Treatment In Early Arthritis Patients
  • Abstract Number: 2508
    Clinical and Serological Discordance In The Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) Cohort
  • Abstract Number: 127
    Clinical Application Of Pain Diagrams In Fibromyalgia
  • Abstract Number: 2020
    Clinical Characteristics In Japanese Patients With IgG4-Related Disease
  • Abstract Number: 328
    Clinical Characteristics Of Patients Who Switch Biologic Therapy Within The First Two Years: Results From a Large US Registry Population
  • Abstract Number: 2478
    Clinical Characteristics Of Patients With Early Spondyloarthritis. Results From a Specialized Consultation In a Clinical Hospital
  • Abstract Number: 2883
    Clinical Characteristics of Rheumatoid Arthritis Patients with Secondary Sjögren’s Syndrome and Association with Joint Damage
  • « Previous Page
  • 1
  • …
  • 35
  • 36
  • 37
  • 38
  • 39
  • …
  • 193
  • Next Page »
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology